Dr Matthew Morgan MB ChB, PhD, FRCP, PGCert, FHEA

Dr Matthew Morgan

Institute of Clinical Sciences
Deputy Programme Director MBChB
Clinical Senior Lecturer in Renal Medicine

Contact details

Address
Institute of Clinical Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Morgan is a Clinical Senior Lecturer in Renal Medicine in the Institute of Clinical Sciences. He is Deputy Programme Director of the MBChB Programme (Medicine and Surgery).

He has an interest in the pathogenesis and treatment of inflammatory renal disease including anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis. He is a member of the European Vasculitis Study Group (EUVAS - http://www.vasculitis.org).

His main interests in ANCA associated vasculitis are treatments for vasculitis that may reduce disease and treatment associated morbidity and mortality and improved quality of life for patients.
Matthew has published a significant number of original research papers in this field as well as book chapters and review articles.

As Deputy Programme Director for the MBChB Programme he has responsibility for the curriculum and assessments including standard setting and innovating new educational practices.

In clinical practice Dr Morgan works as an Honorary Consultant Nephrologist at University Hospitals Birmingham NHS Foundation Trust.

With Professor Lorraine Harper he runs the Vasculitis Clinic at UHB NHS Foundation Trust. This is a multidisciplinary clinic seeing patients with mostly ANCA associated vasculitis (Wegener’s granulomatosis/granulomatosis with polyangiitis, microscopic polyangiitis, Churg-Strauss Syndrome/eosinophilic granulomatosis with polyangiitis) as well as other primary vasculitides. This tertiary referral clinic sees patients from the West Midlands region as well as further afield within the UK.

Qualifications

  • Fellow of the Higher Education Academy 2016
  • Fellow of the Royal College of Physicians (London) 2016
  • Post Graduate Certificate Academic Practice (Distinction) 2016
  • Certificate of Completion of Specialist Training (Renal Medicine) 2009
  • PhD in Immunology (Birmingham) 2007
  • Membership of the Royal College of Physicians (London) 1998
  • MBChB (Birmingham) 1995 

Biography

Matthew qualified in Medicine from the University of Birmingham in 1995. He completed his general basic training and higher professional training in various hospitals in the West Midlands region. He was appointed as Clinical Senior Lecturer/Honorary Consultant Nephrologist in 2009. 

Matthew teaches on a wide variety of courses at undergraduate and post-graduate level. He was involved in the development and GPhC approval of the MPharm course at University of Birmingham. Since 2014 he has been the Academic Lead for Year 4 of the MB ChB Programme with responsibility for the Clinical Course in year 4, its curriculum and assessment as well as overall responsibility for the provision of e-Learning materials. As Deputy Programme Director he has led on developing training and engagement activities for senior clinical NHS staff involved in educating medical students. He also has an interest in developing more inclusive placement experiences for students. 

He completed a PhD in Immunology at the University of Birmingham between 2003 and 2006 investigating the role of T-cells and cytokines in ANCA associated vasculitis. Recent clinical studies have examined the causes of potential treatments for chronic fatigue in patients with ANCA vasculitis and the beneficial effects of blocking subclinical CMV reactivation. 

Matthew is one of the consultants running the Birmingham Vasculitis Clinic at University Hospitals Birmingham. The clinic is a multidisciplinary centre of excellence for the management of vasculitis and delivers numerous observational, experimental medicine and clinical trials in ANCA vasculitis. This has facilitated patient participation in the EUVAS clinical trials to improve treatment for ANCA vasculitis. It has also permitted the development of clinical and translational studies investigating the chronic consequences of inflammation and immunosuppression in patients, particularly the effects on cardiovascular disease, immunodeficiency and infection.

Teaching

Other activities

  • 2016 GMC Recognised Trainer for Undergraduate Education
  • 2015 GMC Accredited Clinical and Educational Supervisor
  • 2015-2017 Renal Medicine subject expert for Medical Schools Council Assessment Alliance Expert Item Review Meetings
  • 2014 onwards mentor for University of Birmingham LGBT Mentoring Scheme
  • 2013-2017 Consultancy work for Sphere Medical Ltd
  • 2012-2015 Patient Information Lead for Rarerenal.org vasculitis
  • 2012-2017 Steering committee member for the UK and Ireland Vasculitis Society
  • 2009 - 2017 NIHR/Wellcome Trust Birmingham Clinical Research Facility Scientific Advisory Committee

Publications

Publications since 2015

Morgan MD, Thomas CP, Coleman JJ,  Atterbury M. Asking students about their experiences during placements. Page 29 in Ward, Nicki and Gale, Nicola (2016) LGBTQ-inclusivity in the Higher Education Curriculum: a best practice guide. Birmingham: University of Birmingham

Chanouzas D, Sagmeister M, Dyall L, Sharp P, Powley L, Johal S, Bowen J, Nightingale P, Ferro CJ, Morgan MD, Moss P, Harper L.The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. Arthritis Research and Therapy in press.

Chanouzas D, Sagmeister M, Faustini S, Nightingale P, Richter A, Ferro CJ, Morgan MD, Moss P,  Harper L.Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in ANCA-associated vasculitis. J Infect Dis 2018. https://doi.org/10.1093/infdis/jiy493

Wall NA, Dominguez-Medina CC, Faustini SE, Cook CN, McClean A, Jesky MD, Perez-Toledo M, Morgan MD, Richter AG, Ferro CJ, Cockwell P, Moss PA, Henderson IR, Harper L, Cunningham AF. Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. PLoS One. 2018 Apr 16;13(4):e0195730. doi: 10.1371/journal.pone.0195730.

Maybury C, Morgan MD, Smith R, Harper L. How does the outcome of research training fellowships funded via the NHS compare with that from competitively funded fellowships from the MRC and other charities: a cross-sectional retrospective survey of trainees undertaking research training in the West Midlands. BMJ Open. 2018 Jan 23;8(1):e019630. doi: 10.1136/bmjopen-2017-019630

Morgan MDSzeto MWalsh MJayne DWestman KRasmussen NHiemstra TFFlossmann OBerden AHöglund PHarper LEuropean Vasculitis Society. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther. 2017 Jun 7;19(1):129. doi: 10.1186/s13075-017-1321-1.

Chanouzas D, Dyall L, Nightingale P, Ferro C, Moss P, Morgan MD, Harper L. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. Trials (2016) 17:338. DOI 10.1186/s13063-016-1482-2

McClean A*, Morgan MD*, Basu N, Bosch JA, Nightingale P, Jones D, Harper L. Physical Fatigue, Fitness and Muscle Function in Patients with Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis. Arthritis Care Res 2015 DOI: 10.1002/acr.22827 Joint first authors

Morgan MD, Richter A, Al-Ali S, Flint J, Yiannakis C, Drayson M, Goldblatt D, Harper L. Low B cells and IgG are associated with infection, while poor vaccine response predicts all-cause mortality in an immunosuppressed vasculitis population.Arthritis Care Res 2015 doi: 10.1002/acr.22757

Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DRW, Geetha D. Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab. Am J Nephrol 2015; 41(4-5):296-301. DOI:10.1159/000431336

Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, Eriksson P, Seo P, Manno RL, Dale J, Harper L, Tesar V,  Jayne DRW. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. J Nephrol 05/2015; DOI:10.1007/s40620-015-0208-y

Wuhrer M, Stavenhagen K, Koeleman CAM, Selman MHJ, Harper L, Jacobs BC, Savage COS, Jefferis R, Deelder AM, Morgan MD. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation and sialylation. J Protesome Res 2015DOI: 10.1021/pr500780a

Jones RB, Furuta S, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR; for the European Vasculitis Society (EUVAS). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015 Mar 4. pii: annrheumdis-2014-206404. doi: 10.1136/annrheumdis-2014-206404.

Croft AP, Smith SW, Carr S, Youssouf S, Salama AD, Burns A, Pusey CD, Hamilton P, Brown N, Venning M, Harper L, Morgan MD. Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody–associated small vessel vasculitis. Kidney Int 2014 doi: 10.1038/ki.2014.329

KiprianosAP, Morgan MD, Little MA, Savage COS, Harper L, Bacon PA, Young SP. Elevated active secretory sphingomyelinase in ANCA-associated primary systemic vasculitis. Annals Rheum Dis 2012;71(6):1100-2

Battula N, Tsapralis D, Morgan M, Mirza D. Spontaneous liver haemorrhage and haemobilia as initial presentation of undiagnosed polyarteritis nodosa. Ann R Coll Surg Engl 2012; 94: e163–e165 doi 10.1308/003588412X13171221590737

Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, de Groot K, Luqmani R, Flores-Suarez LF, Watts R,  Pusey CD, Bruchfeld A, Rasmussen N, Blockmans D, Savage COS, Jayne D on behalf of EUVAS investigators. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated Vasculitis- Long term Follow up. Annals Rheum Dis 2011 doi:10.1136/annrheumdis-2011-200477.

Holden NJ, Williams JM, Morgan MD, Challa A, Gordon J, Pepper RJ, Salama AD, Harper L, Savage COS. ANCA stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011;70:2229-33.

Morris H, Morgan MD, Woods A, Smith SW, Ekeowa UI, Butherus K, Holle JU, Guillevin L, Lomas DA, Perez J, Pusey C, Salama AD, Stockley R, Wieczorek S, McKnight AJ, Maxwell AP, Miranda E, Williams J, Savage CO, Harper L. ANCA-associated vasculitis is associated with carriage of the Z allele of α1antitrypsin and its polymers. Annals Rheum Dis 2011;70:1851-6

Morgan MD, Pachnio A, Begum J, Roberts D, Rasmussen N, Neil DAH, Bajema I, Savage COS, Moss PA, Harper L. CD4+CD28- T-cell expansion in Wegener’s granulomatosis is driven by latent CMV and is associated with an increased risk of infection and mortality. Arthritis Rheum 2011;63:2127-37. 

Smith HJ, Hanvesakul R, Bentall A, Shabir S, Morgan MD, Briggs D, Cockwell P, Borrows R, Larche M,  Ball S. T lymphocyte responses to non-polymorphic HLA derived peptides are associated with chronic renal allograft dysfunction. Transplantation. 2011;91:279-86

LandrayMJ, Emberson  J, Blackwell L, Dasgupta T, Zakeri , Morgan MD, Ferro C, Vickery S, Ayrton P, Nair D, Dalton  RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC. Prediction of end-stage renal disease and death among people with chronic kidney disease: the Chronic Renal Impairment in Birmingham (CRIB) study. Am J Kidney Dis 2010; 56: 1082-1094.

Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J , Howie A, Ghonemy T,  Rajabali S, Roberts D, White L, Khan S, Morgan MD, Cockwell P, Hutchison C. The incidence of major hemorrhagic complications following renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol. Epub July 22nd 2010 doi: 10.2215/CJN.00650110.

Smith HJ, Hanvesakul R, Morgan MD, Bentall A, Briggs D, Clark F, Pratt G, Moss P, Larché M, Ball S. Chronic graft versus host disease is associated with an immune response to autologous HLA-derived peptides. Transplantation. 2010: 90; 555-63

Morgan MD, Drayson MT, Savage COS, Harper L. Addition of Infliximab to standard therapy for Anti-Neutrophil Cytoplasm Antibody associated vasculitis. Nephron Clin Pract 2010;117:89-97.

Jones RB, Cohen Tevaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Passen P, Walsh D, Walsh M, Westmann K, Jayne DRW on behalf of the European Vasculitis Study Group. Randomised trial of rituximab versus cyclophosphamide in ANCA associated renal vasculitis ‘RITUXVAS’. New Eng J Med 2010: 363; 211-220

Morgan MD, Day CJ, Piper KL, Khan N, Harper L, Moss P, Savage COS. Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T regulatory cells. Immunology 2010;130:64-73

Reviews

Peracha J, Morgan MD. Urological manifestations and treatment of the primary systemic vasculitides. World J Clin Urol 2015;4(1):5-20 doi:10.5410/wjcu.v4.i1.5.

Dyall L, Chanouzas D, Morgan MD. Evidence based therapy for the ANCA-Associated Vasculitides: what do the trials show so far? Clinical Investigation 2014;4 (10):951-968 doi: 10.4155/cli.14.66

Chanouzas D, Morgan MD. Advances in therapies for ANCA associated vasculitides. International Journal of Advances in Rheumatology 2011;9(3):85–94.

Kett CE, Morgan MD, Harper L. Therapy for ANCA-associated vasculitis. Journal of Clinical Rheumatology and Musculoskeletal Medicine 2010;2(1)

Flint J, Morgan MD, Savage COS. The Pathogenesis of ANCA associated vasculitis. Rheum Dis Clin North Am 2010; 36: 463-477

Book chapters

Geh D, Chanouzas D, Morgan MD. Systemic Vasculitis of the Gastrointestinal Tract. In The Vasculitides 2nd Edition, Edited by David S Younger, Nova Science Publishers, New York in press.

Tracy A, Yiannakis D, Ward L, Morgan MD. Classification and Pathogenicity of ANCA-Associated Vasculitis. In The Vasculitides 2nd Edition, Edited by David S Younger, Nova Science Publishers, New York in press.

Morgan MD, Smith SW, Savage COS, Leung JCH. The Vasculitides. In ABC of arterial and venous disease 3rd Edition, edited by Timothy England. Wiley Publishing Ltd. ISBN 978-1-118-89070-7.

Chanouzas D, Morgan MD. Systemic Vasculitis of the Gastrointestinal Tract. In The Vasculitides, Edited by David S Younger, 2015 Nova Science Publishers, New York. ISBN 978-1-63463-110-5.

Yiannakis D, Ward L, Morgan MD. Classification and Pathogenicity of ANCA-Associated Vasculitis. In The Vasculitides, Edited by David S Younger, 2015 Nova Science Publishers, New York. ISBN 978-63463-112-9

Banham GD, Morgan MD, Savage COS. Autoantibodies to endothelial cells. In Encyclopedia of Medical Immunology. Edited by Ian R Mackay, Noel R Rose, Betty Diamond, Anne Davidson, 2014 Springer Link, New York. Print ISBN 978-0-387-84827-3, online ISBN 978-0-387-84827-0, DOI 10.1007/978-0-387-84827-0

Morgan MD, Savage COS. Neutrophils in vascular inflammation. In Inflammatory diseases of blood vessels. Edited by Gary Hoffman, Cornelia Weyand, Carol Langford and Jorg Goronzy 2012. Blackwell Publishing Ltd, Oxford, UK. ISBN: 978-1-4443-3822-5.

View all publications in research portal